SCHEMBL7424856

SCHEMBL7424856

Clc1nc2cccc3c2n1CCC3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
MCL1 Q07820 2/20 0.43
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 3/20 0.40
USP2 O75604 2/20 0.40
HPGD P15428 1/20 0.40
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
KDM4E B2RXH2 2/20 0.36
CYP1A2 P05177 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
BCHE P06276 1/20 0.36
CFTR P13569 1/20 0.36
ALOX15 P16050 1/20 0.36
ACHE P22303 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
GOPC Q9HD26 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057519 0.80 NPC1 (0.50) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL10633577 0.80 NPC1 (0.50) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL18628737 0.80 NPC1 (0.50) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL9078237 0.80 NPC1 (0.56) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL4947911 0.80 NPC1 (0.60) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL6507233 0.78 PARP1 (0.42) NPC1MAPTRAB9AHSD17B10ALDH1A1
SCHEMBL8548519 0.76 MAPT (0.47) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL4768227 0.76 NPC1 (0.60) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL18853940 0.76 NPC1 (0.60) NPC1MAPTRAB9AMCL1HSD17B10
SCHEMBL2080582 0.76 NPC1 (0.47) NPC1MAPTRAB9AMCL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0700913-B1 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds HOECHST MARION ROUSSEL INC (US) 1998-06-03 EP claimed
EP-0700913-A1 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1996-03-13 EP claimed
JP-8092251-A None JP disclosed
JP-7179466-A None JP disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2015-10-01 US disclosed
EP-0700913-B1 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds HOECHST MARION ROUSSEL INC (US) 1998-06-03 EP disclosed
US-5589476-A TREATMENT OF NAUSEA, VOMITING AND GASTROINTESTINAL DISORDERS SYNTHELABO (FR) 1996-12-31 US disclosed
US-5563272-A ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1996-10-08 US disclosed
JP-H0892251-A 5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINES, THEIR PRODUCTION, USE THEREOF AS MEDICAMENT AND INTERMEDIATE COMPOUND HOECHST ROUSSEL PHARMACEUT INC 1996-04-09 JP disclosed
US-5500423-A ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1996-03-19 US disclosed
EP-0700913-A1 5,6-dihydro-4H-imidazo(4,5,1-ij)quinolines, processes for their preparation, their use as medicaments, and intermediate compounds HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1996-03-13 EP disclosed
JP-H07179466-A IMIDAZOL-4-YLPIPERIDINE DERIVATIVE, ITS PREPARATION, AND APPLICATION THEREOF IN MEDICINE SYNTHELABO SA 1995-07-18 JP disclosed
EP-0646583-A1 Derivatives of Imidezol-4-yl piperidine, their preparation and use in therapy SYNTHELABO (FR) 1995-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS CDK8, CDK18, CDK9 NPC1 4696/4885MAPT 3120/4885RAB9A 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.